A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of *Mycobacterium tuberculosis*

Sandeep Kumar Dhanda, Pooja Vir, Deepak Singla, Sudheer Gupta, Shailesh Kumar, Gajendra P. S. Raghava*

Bioinformatics Centre, Institute of Microbial Technology, Chandigarh, 160036, India

* raghava@imtech.res.in

Abstract

Development of an effective vaccine against drug-resistant *Mycobacterium tuberculosis* (MtB) is crucial for saving millions of premature deaths every year due to tuberculosis. This paper describes a web portal developed for assisting researchers in designing vaccines against emerging MtB strains using traditional and modern approaches. Firstly, we annotated 59 genomes of Mycobacterium species to understand similarity/dissimilarity between tuberculoid, non-tuberculoid and vaccine strains at genome level. Secondly, antigen-based vaccine candidates have been predicted in each MtB strain. Thirdly, epitopes-based vaccine candidates were predicted/discovered in above antigen-based vaccine candidates that can stimulate all arms of immune system. Finally, a database of predicted vaccine candidates at epitopes as well as at antigen level has been developed for above strains. In order to design vaccine against a newly sequenced genome of MtB strain, server integrates three modules for identification of strain-, antigen-, epitope-specific vaccine candidates. We observed that 103522 unique peptides (9mers) had the potential to induce an antibody response and/or promiscuous binder to MHC alleles and/or have the capability to stimulate T lymphocytes. In summary, this web-portal will be useful for researchers working on designing vaccines against MtB including drug-resistant strains. Availability: The database is available freely at http://crdd.osdd.net/raghava/mtbveb/.

Introduction

The tuberculosis cost millions of lives every year globally as well as billions of humans are infected with this deadly disease [1,2]. In addition, treatment is not patient friendly, as it requires combination of drugs for six months. The emergence of drug-resistant MtB strains further complicating the problem as existing drugs are not effective against these strains [3,4]. Fortunately, BCG based vaccination against tuberculosis is available since 1921 that is responsible for saving millions of death every year [5]. BCG based vaccine is highly protective in case of children and in developed countries, but the efficacy is questionable for adults, immunocompromised individuals, and the residents of developing nations where it was most needed [6]. There are various reasons suggested for the BCG failures, some of them are as variation in the
strains of BCG vaccine (nobody knows which strains is best protective), environmental expo-
sure to Nontuberculous Mycobacteria (NTM) strains (interfere with immune response to be 
elicted by vaccine strain possibly due to neutralizing antibodies) [7,8]. There is a need to 
address this problem in modern era using latest techniques like next generation sequencing 
(NGS) and virtual screening of epitopes.

In the era NGS, the entire microbial genomes can be sequenced at affordable cost within 
hours [9]. These newly sequenced strains may have the potential to act as the vaccine strain, 
but there is no platform for predicting vaccine potential of a strain. In the literature, some key 
points have been mentioned as the requirement of a vaccine strain for tuberculosis [10]. These 
points include the involvement of virulence factors, ESX system [11] and the proteins from 
region of genetic variance [12]. The second challenge for tuberculosis vaccine is desired 
immune response. The desired immune response to tuberculosis vaccine has been reported in 
the literature [13–15]. The desired immunity includes cell-mediated immune response charac-
terized by MHC binders and Th1 activating environment [16–18]. The role humoral immunity 
is also not clearly understood and well established [6,19].

In this study, we have made an attempt to develop a comprehensive database or web portal 
for designing vaccine against large number of mycobacterium strains whose whole genome 
have been already sequenced. In addition, tools have been integrated in this web portal that 
allow users to identify vaccine candidates against a new strain (e.g., emerging strain, drug resis-
tant) from their whole genome sequence. In this study, first we identified 178 antigens based 
on previous studies, which are potential vaccine candidates. We developed immune-informat-
ics pipeline that automatically predict different types of antigenic regions or epitopes required 
for activating different arms of immune system. Identification of conserved regions in a vaccine 
candidate is one of the challenge in designing vaccine against a strain of *Mycobacterium* [20]. In 
order to address this issue our server aligns new antigen/vaccine candidates against similar 
antigens in other strains of *Mycobacterium* for identification of conserved region from multiple 
sequence alignment. In summary our database provides vaccine related information about 59 
strains and provide facility to identify vaccine against new strain from their genome sequence. 
Therefore, the aim of the present study is to develop a web portal for comprehensive study of 
mycobacterial strains and vaccine candidates for designing better vaccine against tuberculosis.

**Methods**

**Strains**

We downloaded whole genome of 59 Mtb strains with complete (chromosome) annotation 
from the NCBI [21]. We selected genomes based on certain criteria’s that includes availability 
of complete genome in NCBI and annotation of genome at chromosome level. These strains 
belong to diverse category of pathogenesis, drug-resistance, drug-sensitive, clinical isolates, lab 
strains, non-tuberculoid and vaccine strains (Figure A in S1 File). Following is brief description 
of these three types strains

**Tuberculoid strain.** The mycobacterium strains that can cause tuberculosis infection are 
called tuberculoid strains. We compiled wide-range of tuberculoid strains that includes drug-
sensitive, multi drug-resistant, extensively drug-resistant and clinical isolates. In this study we 
have collected and compiled genomics information about 23 tuberculoid strains.

**Vaccine strains.** In this study, we compiled genomic information about five M. bovis vac-
cine strains (e.g., AF2122/97, BCG strain Korea, BCG strain Tokyo 172). These tuberculosis 
vaccine strains are attenuated bovine strains named as Bacillus Calmette Guerin (BCG). The 
vaccine strain is sub-cultured in many labs around the world and had undergone several varia-
tions in the genome. Among them, four vaccine variants have been sequences and annotated at
chromosome level. We have categories these four variants and their parental vaccine strains under vaccine strain groups.

**Non-tuberculoid strains.** The mycobacterial strains that do not cause active tuberculosis in human are called non-tuberculoid mycobacterium (NTM). Most of the NTM are environmental mycobacteria, but some of NTM may be opportunistic pathogen, which can cause disease in immune compromised individuals. Here, we have total 30 NTM strains that include the strains causing leprosy and ulcer.

**Vaccine candidates**

One of the challenges in designing subunit-vaccine is identification of potential vaccine candidate. Though a mycobacterium strain have around 4000 proteins only limited proteins are potential vaccine candidates [22]. We collected and compiled potential vaccine candidates from previous studies [14]. In this study, we have taken strain H37Rv as reference strain for identification of potential vaccine candidates. These vaccine candidates belong to three categories as given below.

**Virulence associated proteins.** The proteins associated with the virulence of tuberculosis are attractive vaccine targets. PPE family serves as the best example, which has been explored widely for vaccine potential [23–25]. We have obtained the 125 virulence factors from Mycobacterium tuberculosis which were beautifully summarized in review article [26].

**Components of secretion system.** Secretion system from tuberculosis is extensively exploited for hunting a new vaccine candidate and as a result some of the candidates like ESAT-6 and antigen85 are running in clinical trials [27–29]. Champion and Cox had reviewed the protein secretion system from *Mycobacterium tuberculosis* [30]. We have extracted the 20 components of secretion system from this review for vaccine candidates.

**Regions of deletion.** The BCG vaccine has been developed from a bovine virulent strain. During the process of attenuation several proteins has undergone mutation and variation. The region of deletion (RD) is supplemented to BCG to create recombinant BCG (rBCG) to provide better protection [31–33]. Gunawardena et. al. compared the membrane proteins of virulent and vaccine strains of tuberculosis [34]. They identified proteins that show genetic variance between virulent and vaccine strains. In this study, we obtained 33 vaccine targets from above study.

Overall we obtained total 178 (166 unique) vaccine candidates for Mycobacterium strain H37Rv, which contain 125 virulent, 22 secretory and 33 RD proteins.

**Vaccine candidates in other strains.** In order to identify vaccine candidates in other strains of Mycobacterium, we perform similarity search of these 178 vaccine candidates (in strain H37Rv) against whole proteome of these strains. Similarity, search was performed using needleall software of emboss package and selected those proteins as vaccine candidate that have highest identity with cut-off 95%. The numbers of vaccine candidates identified using above similarity search is shown in Table A in S1 File.

**Epitope or antigenic regions**

Experimentally validated epitopes: We obtained experimentally validated or characterize epitopes from Immune Epitope Database (IEDB), largest database of epitopes [35]. These epitopes were collected from four types of assays includes B-cell response, MHC binding and T cell response assays. We map these epitopes on vaccine candidates to identify antigenic regions or epitopes in vaccine targets.

**Prediction of epitopes.** In order to predict epitopes in vaccine targets, first we generate all possible overlapping 9mer peptides in vaccine targets. Next, we remove redundant or duplicate
peptides from these 9mer peptides. Finally, we used a pipeline for predicting different types of epitopes in these 9mer peptides. This pipeline predict; i) B-cell epitopes using Lbtope [36], ii) MHC class I & II binders using Propred/Propred1 [37–39] and iii) T-cell epitopes using software CTLpred, IFNepitope and IL4pred [40–42]. We have selected the peptides with desired immune response; see Figure B in S1 File for flow diagram used in this study.

Database architecture & platform

The architecture of database is shown in Fig 1 that organized data in three categories strain, vaccine candidates and epitopes. In order to manage data efficiently, we used relational data management system (RDBM) implemented using MySQL server. This web site is launched using Apache HTTP Server 2.2 on a linux operating system. All web interfaces has been developed using HTML and PHP 5.2.9. In addition JavaScript is used for number of functions including visualizing of genomes.

Result

Analysis of vaccine candidates

We compute length-wise distribution of 166 unique vaccine targets (Total 178) to understand length-wise distribution. It was observed that length of vaccine candidates varies from 48 to 2126 amino acids. Most of the vaccine candidates have number residues between 100 to 600 (Figure C in S1 File). We examine whether these three types of vaccine targets (125 virulent, 20 secretory and 33 RD proteins) can be used to discriminate different types of strains. Thus we predict presence of these antigens in each strain based on their similarity with target antigens in tuberculosis strain. It was observed that 125 virulent and 20 secretory proteins can discriminate pathogenic and non-pathogenic variants of mycobacteria, but these proteins could not differentiate vaccine strains from the pathogenic strains (Fig 2 and Figure B and Table C in S1 File). Our 33 vaccine targets RD proteins could discriminate vaccine strains from the pathogenic strains (Table D in S1 File). The supplementary data shows the number of homologous proteins (with sequence identity cut off 95 percent) extracted out of various pathogenic strain
and these homologs were then searched in different non-tuberculoid mycobacterial (NTM) strains. It is to be noted here that there were no difference in number of proteins in Mycobacterium africanum GM041182 (tuberculoid strain) [43] and variant of BCG, when we searched 125 virulent proteins and 20 ESX secretion system proteins. On the other hand, we observed significant difference when we searched the homologs of 33 proteins of genetic variance. We annotate virulent proteins to understand their function and role in bacterial system, information was extracted from UniProt database [44]. We extracted detailed about each protein like cellular components, pathways, motifs, link to other databases, and gene ontology (Figure D in S1 File). We end up 125 proteins, which localized in various part of the cell as depicted in Figure E in S1 File. As it evident from Fig 2 that half of our proteins are component of plasma membrane or cell wall and 11% are extracellular proteins.

Epitope mapping and prediction

We mapped experimentally validated epitopes (available in IEDB database) on 59 strains of mycobacterium strains (Table 1, Figure F in S1 File). As shown in Table 1, 659 B-cell epitopes in IEDB mapped on 30992 segments of mycobacterium strains. It is interesting to note that out of 659 epitopes, 628 epitopes were mapped on vaccine candidates. It means most of B-cell epitopes were obtained from candidates. In case of T-cell epitopes, 1806 were mapped on strains and 1063 on vaccine candidates. In addition to mapping of experimentally validated epitopes, we also predicted epitopes in above vaccine candidates using prediction software. First, we generate unique 9mer peptides in vaccine candidates in all strains and obtained total 103522 unique peptides (Table 2). Out of these peptides, 8292 peptides were predicted to be linear B-cell epitopes. There were 14907 potential MHC class II binders, 46484 MHC class I binders. Out of 46484 MHC class I binders, 34922 peptides were predicted to induce cytotoxic T lymphocytes. On the other hand, there were 391 peptides that can produce Th1 immunity and humoral response. We hope these peptides have the potential for a subunit vaccine.
Web Implementation of MtbVeb

In this database, data is compiled in three sections for designing strain, antigen and epitope based vaccine. In order to retrieve and analysis vaccine related data in our database, we integrated various web-based tools. Following is the brief description of menus and submenus incorporated in MtbVeb database for designing vaccines based on strain, antigen and epitope.

### Strain-specific information

This menu allows users to identify most appropriate strain for designing vaccine against a pathogenic strain. It also allows users to analysis their newly sequenced mycobacterium strain. This menu comprise various submenus allow users to access data at strain level. First submenu “Browse on strains” list all strains maintained in this database with their type and brief description. User can check experimentally validated epitopes mapped on different strains using “Browse on Epitopes” submenu. In order to compare vaccine targets in different strains, server presents multiple sequence alignment of each target in different strains. This can be achieved using “Strain-wise comparison” submenu; in addition user can identify conserved regions in vaccine targets from their multiple sequence alignment. Submenus identify vaccine strain, designed for identification of appropriate vaccine strain based on different class of vaccine candidates present in these strains. Analysis of user strain is an important submenu that allows users to analysis genomic information provides in any form like short reads, contigs. We integrated three well-known genome browsers (e.g., JBrowse, CGView, Argo) in our database for visualization of genome of strains.

### Table 1. Mapping of experimentally characterized epitopes/MHC-binders on all antigens and vaccine candidates of mycobacterium strains.

| Epitopes / Binders | Whole Mycobacterium Strains | Only on Vaccine Candidates |
|--------------------|-----------------------------|---------------------------|
|                    | Total Peptides | Unique Peptides | Total Peptides | Unique Peptides |
| B-cell epitope      | 30992         | 659             |             | 628             |
| T-cell epitope      | 142265        | 1806            |             | 1063            |
| MHC binders         | 180726        | 1208            |             | 387             |

doi:10.1371/journal.pone.0153771.t001

### Table 2. List of 9mer peptides, epitopes, MHC binders in vaccine candidates.

| Filter ID | Filter | Genetic Variance | Secretion | Virulent | Total (Unique) |
|-----------|--------|------------------|-----------|----------|----------------|
| ID1       | Proteins | 33 | 20 | 125 | 166          |
| ID2       | 9mer peptides | 230509 | 121895 | 1366365 | 1718769 |
| ID3       | Unique 9mer | 12941 | 7566 | 87097 | 103522 |
| ID4       | LBtope | 1090 | 661 | 6899 | 8292 |
| ID5       | Propred1 | 8954 | 5029 | 34899 | 46484 |
| ID6       | CTLpred | 2132 | 1000 | 55839 | 58492 |
| ID7 (ID5 + ID6) | CD8 epitopes | 2028 | 969 | 32329 | 34922 |
| ID8       | Propred | 1847 | 968 | 12632 | 14907 |
| ID9       | IFNepitope | 5276 | 3114 | 36594 | 43489 |
| ID10 (ID8 + ID9) | Th1 epitopes | 776 | 359 | 5294 | 6242 |
| ID11      | IL4pred | 8769 | 4852 | 57089 | 67952 |
| ID12 (ID8 + ID11) | Th2 epitopes | 1241 | 619 | 8216 | 9720 |
| ID13 (ID10 + ID4) | Th1 + B cell | 62 | 25 | 318 | 391 |
| ID14 (ID10—ID4) | Th1—B cell | 714 | 334 | 4976 | 5851 |

doi:10.1371/journal.pone.0153771.t002
Antigen-based vaccines

In order to develop antigen-based vaccine against a pathogenic strain, we integrate tools for identification of most appropriate vaccine candidates. This menu has number of submenus to retrieve comprehensive information about each antigen in any mycobacterium strains. Once can retrieve sequence related information of 178 vaccine candidates or antigens in a strain using submenu "Browse on Antigens". User may get detail information about each antigen using antigen card. Submenu "Browse Vaccine Targets" of server shows presence or absence of vaccine targets in 59 mycobacterium strains. Similarly, other submenus under this menu allow users to perform similarity search, alignment and epitope mapping on query sequence. [45].

Epitope Prediction

In present era major focus of researchers in on micro minimization of vaccines from strain to antigen to epitope. This menu developed for predicting epitopes suitable for designing epitope-based vaccine against a mycobacterium strain. The browse submenu allow users map predict epitopes on vaccine candidates; it includes predicted B-cell and T-cell epitopes. It is possible to perform complex search on predicted epitopes using submenu “Advance Search”. We allow users to list most potential epitopes having potential to activate desired immune response. User can predict epitopes in their antigen sequence using prediction pipeline used in this study.

Limitation of MtbVeb

Although we have tried our best to develop a platform to provide comprehensive information required for developing vaccine or immunotherapy against *M. tuberculosis*. Still it has number of limitations that need to be addressed in future studies. This platform provides no information about the formulation of peptides with different adjuvants for better immunization. Due to technological advances whole genome sequencing of strains is growing with exponential rate. Thus server needs to be updated frequently to incorporate information about newly sequenced strains.

Discussion

Presently only limited options are available to fight against deadly infectious disease tuberculosis; BCG is only vaccine. In past it has been shown that BCG provides limited protection against tuberculosis particularly adults. There is a continuous effort by scientific community to improve BGC strains in order to enhance effectiveness [46,47]. Alternatively, researchers are searching new vaccine strains, which may provide protection against pathogenic strains particularly against emerging drug resistant strains. Fortunately whole genome of wide range of mycobacterium strain has been sequenced and available in public domain. There is a need to analysis whole genome sequence of theses newly sequenced strain for identification of most appropriate vaccine strain. In this study we made a systematic attempt to develop computational tools and database for identification vaccine strain against a given pathogenic strain.

In addition to strain-specific vaccines, researchers are focusing on antigen-based vaccines where major emphasis is on identification of potential antigen. Several vaccine candidates have been identified in previous studies and some of these candidates are also running in clinical trials [48–52]. In the past, researchers have developed databases and prediction tools pertaining to tuberculosis vaccine research. He et al. developed a platform named as ‘Violin’ for vaccine information [53]. Violin covers several aspects of vaccines like vaccine components, mechanism, design, and community. For tuberculosis vaccine policies, Zwerling et al. has developed a tool [54]. MycobacRv is another database related to TB vaccine [55]. MycobacRv has limits its
focus to adhesion proteins in the genomes of different mycobacterial species. None of the existing tools is providing a solution to design a vaccine for emerging strains. As shown in Table 3, our MtbVeb had more features than existing resources. Thus our server will complement existing resources in the field of vaccines against *M. tuberculosis*. The major facilities in our web platform includes, i) prediction of new epitopes, ii) mapping of already known epitope and iii) automatic pipeline for identification of epitopes. One of the major features of our web server is analysis of data at antigen and strain-level.

In this study we also made systematic attempt to design antigen and epitope based vaccine. First we identified potential vaccine candidates from literature that have been extensively studied in past. These vaccine candidates have been searched in all strains whose genome sequence is available. All the information required for developing antigen-based vaccines against mycobacterium strains have been compiled in for of a database MtbVeb. We also mapped experimentally validated and predicted epitopes on above potential vaccine candidates. This information will be very useful in designing epitope-based vaccine against any emerging or existing strain of mycobacterium. We have also filtered 12 peptides that have shown diverse immunity and present in number of tuberculoid strain, but absent in vaccine strains (Table E in S1 File). In summary our database cum web-based platform provides comprehensive information on 59 mycobacterium strains. This comprehensive information and tools integrated in MtbVeb allow one to design computer-aided vaccine based on whole strain, antigen and epitope.

### Supporting Information

S1 File. Supplementary file containing Figures A-F and Tables A-E. (DOCX)

### Author Contributions

Conceived and designed the experiments: GPSR SKD. Performed the experiments: SKD. Analyzed the data: SKD PV. Contributed reagents/materials/analysis tools: DS SK SG. Wrote the paper: SKD GPSR. Made suggestions in the project: PV.

### References

1. Dye C. Global epidemiology of tuberculosis. Lancet. 2006; 367: 938–40. doi: 10.1016/S0140-6736(06)68384-0 PMID: 16546542

2. Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol. Elsevier; 2013; 21: 493–501. doi: 10.1016/j.tim.2013.05.002

3. Dalton T, Cegielski P, Akksip S, Asencios L, Campos Caoli J, Cho S-N, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight
countries: a prospective cohort study. Lancet. 2012; 380: 1406–17. doi: 10.1016/S0140-6736(12)60734-X PMID: 22938757

4. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010; 10: 621–9. doi: 10.1016/S1473-3099(10)70139-0 PMID: 20797644

5. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, et al. The influence of bacille Calmette-Gue´rin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med. 2012; 185: 213–22. doi: 10.1164/rccm.201104-0714OC PMID: 22071384

6. Andersen P, Doherty TM. The success and failure of BCG—implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005; 3: 566–62. doi: 10.1038/nrmicro1211 PMID: 16012514

7. Rook GAW, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Vaccine. 2005; 23: 2115–20. doi: 10.1016/j.vaccine.2005.01.069 PMID: 15755581

8. Behr MA. BCG—different strains, different vaccines? Lancet Infect Dis. 2002; 2: 86–92. Available: http://www.ncbi.nlm.nih.gov/pubmed/11901655 PMID: 11901655

9. Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet. Nature Publishing Group; 2013; 14: 618–30. doi: 10.1038/nrg3542 PMID: 23897237

10. Collins DM. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Immunol Cell Biol. 2000; 78: 342–8. doi: 10.1046/j.1440-1711.2000.00937.x PMID: 10947858

11. McShane H, Williams A. Tuberculosis vaccine promises sterilizing immunity. Nat Med. 2011; 17: 1185–6. doi: 10.1038/nm.2503 PMID: 21988991

12. Young DB. Building a better tuberculosis vaccine. Nat Med. 2003; 9: 503–4. doi: 10.1038/nrn868 PMID: 12692547

13. Andersen P, Doherty TM. TB subunit vaccines—putting the pieces together. Microbes Infect. 2005; 7: 911–21. doi: 10.1016/j.micinf.2005.03.013 PMID: 15878836

14. Doherty TM, Dietrich J, Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin Biol Ther. 2007; 7: 1539–49. doi: 10.1517/14712597.2007.17916046

15. Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology. 2011; 411: 206–15. doi: 10.1016/j.virol.2010.12.016 PMID: 21216425

16. Jalapathy KV, Prabha C, Das SD. Correlates of protective immune response in tuberculous pleuritis. FEMS Immunol Med Microbiol. 2004; 40: 139–45. doi: 10.1016/S0928-8244(03)00303-1 PMID: 14987732

17. Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med. 1994; 97: 459–67. Available: http://www.ncbi.nlm.nih.gov/pubmed/7977435 PMID: 7977435

18. Young SL, Slobbe LJ, Peacey M, Gilbert SC, de Lisle GW, et al. Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis. Immunol Cell Biol. Australasian Society for Immunology Inc.; 2010; 88: 651–9. doi: 10.1038/icb.2007.45 PMID: 20103770

19. Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol. 2009; 157: 235–43. doi: 10.1111/j.1365-2249.2009.03967.x PMID: 19604263

20. Elhay MJ, Andersen P. Immunological requirements for a subunit vaccine against tuberculosis. Immunol Cell Biol. 1997; 75: 595–603. doi: 10.1038/icb.1997.94 PMID: 9492199

21. Galagan JE. Genomic insights into tuberculosis. Nat Rev Genet. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2014; 15: 307–20. doi: 10.1038/nrg3664 PMID: 24662221

22. Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2011; 2: 1057–77. Available: http://www.ncbi.nlm.nih.gov/pubmed/22826868 PMID: 22826868

23. Okkels LM, Brock I, Follmann F, Agger EM, Arend SM, Ottenhoff THM, et al. PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect Immun. 2003; 71: 616–23. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=219556&tool=pmcentrez&rendertype=abstract PMID: 14573626

24. Akhter Y, Ehebauer MT, Mukhopadhyay S, Hasnain SE. The PE/PPE multigene family codes for virulence factors and is a possible source of mycobacterial antigenic variation: perhaps more? Biochimie. 2012; 94: 110–6. doi: 10.1016/j.biochi.2011.09.026 PMID: 22005451
25. Romano M, Rindi L, Korh F, Bonanni D, Adnet P-Y, Jurion F, et al. Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine. 2008; 26: 6053–63. doi: 10.1016/j.vaccine.2008.09.025 PMID: 18822333

26. Forrellad MA, Klepp L1, Gioffré A, Sabio y García J, Morbidoni HR, de la Paz Santangelo M, et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence. 2013; 4: 3–66. doi: 10.4161/viru.22329 PMID: 23076359

27. Simeone R, Bottai D, Frigui W, Majessi L, Brosch R. ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection. Tuberculosis (Edinb). 2015; doi: 10.1016/j.tube.2015.02.019

28. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev. 1992; 56: 648–61. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=372892&tool=pmcentrez&rendertype=abstract PMID: 1480113

29. Bottai D, Frigui W, Clark S, Rayner E, Zeimer A, Andreu N, et al. Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. Vaccine. 2015; 33: 2710–2718. doi: 10.1016/j.vaccine.2015.03.083 PMID: 25869896

30. Champion PAD, Cox JS. Protein secretion systems in Mycobacteria. Cell Microbiol. 2007; 9: 1376–84. doi: 10.1111/j.1462-5822.2007.01094.x PMID: 17466013

31. Kalra M, Grover A, Mehta N, Singh J, Kaur J, Sable SB, et al. Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculosis mice. Clin Immunol. 2007; 125: 173–83. doi: 10.1016/j.clim.2007.07.007 PMID: 17766185

32. Ganguly N, Siddiqui I, Sharma P. Role of M. tuberculosis RD-1 region encoded secretory proteins in immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine. 2008; 26: 6053–63. doi: 10.1016/j.vaccine.2008.09.025 PMID: 18822333

33. Wang J, Zhang H, Wang H. Analysis of predicted CD8+ T cell epitopes from proteins encoded by the small M. tuberculosis specific RD regions of Mycobacterium tuberculosis for vaccine development and specific diagnosis. Mol Biol Rep. 2010; 37: 1793–9. doi: 10.1007/s11033-009-9613-4 PMID: 19609720

34. Gunawardena HP, Feltcher ME, Wrobel JA, Gu S, Braunstein M, Chen X. Comparison of the membrane proteome of virulent Mycobacterium tuberculosis and the attenuated Mycobacterium bovis BCG vaccine strain by label-free quantitative proteomics. J Proteome Res. 2013; 12: 5463–74. doi: 10.1021/pr300334k PMID: 24093440

35. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, et al. The immune epitope database 2.0. Nucleic Acids Res. 2010; 38: D854–62. doi: 10.1093/nar/gkp1004 PMID: 19906713

36. Singh H, Ansari HR, Raghava GPS. Improved method for linear B-cell epitope prediction using antigen’s primary sequence. PLoS One. 2013; 8: e62216. doi: 10.1371/journal.pone.0062216 PMID: 23667458

37. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001; 17: 1236–7. doi: 10.1093/bioinformatics/17.11.1236 PMID: 11751237

38. Singh H, Raghava GPS. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics. 2003; 19: 1009–14. doi: 10.1093/bioinformatics/19.8.1009 PMID: 12761064

39. Bhasin M, Raghava GPS. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. J Biosci. 2007; 32: 31. Available: http://www.ncbi.nlm.nih.gov/pubmed/17426378

40. Bhasin M, Raghava GPS. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004; 22: 3195–204. doi: 10.1016/j.vaccine.2004.02.005 PMID: 15297074

41. Dhanda SK, Vir P, Raghava GPS. Designing of interferon-gamma inducing MHC class-II binders. Bio Direct. BioMed Central Ltd; 2013; 8: 30. doi: 10.1186/1745-6150-8-30 PMID: 23404645

42. Dhanda SK, Gupta S, Vir P, Raghava GPS. Prediction of IL4 inducing peptides. Clin Dev Immunol. 2013; 2013: 263952. doi: 10.1155/2013/263952 PMID: 24489573

43. Bentley SD, Comas I, Bryant JM, Walker D, Smith NH, Harris SR, et al. The genome of Mycobacterium africanum West African 2 reveals a lineage-specific locus and genome erosion common to the M. tuberculosis complex. Small PLC, editor. PLoS Negl Trop Dis. Public Library of Science; 2012; 6: e1552. doi: 10.1371/journal.pntd.0001552 PMID: 22329328

44. Consortium U. Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res. 2012; doi: 10.1093/nar/gks1068

45. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet. 2000; 16: 276–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/10827455 PMID: 10827456

46. Kaufmann SHE. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol. 2012; 33: 373–9. doi: 10.1016/j.it.2012.03.004 PMID: 22560865
47. Andersen P. Tuberculosis vaccines—an update. Nat Rev Microbiol. 2007; 5: 484–7. doi: 10.1038/nrmicro1703 PMID: 17571458

48. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun. 2004; 72: 6148–50. doi: 10.1128/IAI.72.10.6148–6150.2004 PMID: 15385521

49. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003; 9: 533–9. doi: 10.1038/nm859 PMID: 12692540

50. Mukai T, Maeda Y, Tamura T, Matsuoka M, Tsukamoto Y, Makino M. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein. J Immunol. 2009; 183: 6561–8. doi: 10.4049/jimmunol.0803857 PMID: 19846882

51. Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines. Expert Reviews Ltd London, UK; 2011; 10: 645–58. doi: 10.1586/erv.11.28 PMID: 21604985

52. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med. 2010; 2: 53ra74. doi: 10.1126/scitranslmed.3001094 PMID: 20944089

53. He Y, Racz R, Sayers S, Lin Y, Todd T, Hur J, et al. Updates on the web-based VIOLIN vaccine database and analysis system. Nucleic Acids Res. 2014; 42: D1124–32. doi: 10.1093/nar/gkt1133 PMID: 24259431

54. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011; 8: e1001012. doi: 10.1371/journal.pmed.1001012 PMID: 21445325

55. Chaudhuri R, Kulshreshtha D, Raghunandan MV, Ramachandran S. Integrative immunoinformatics for Mycobacterial diseases in R platform. Syst Synth Biol. 2014; 8: 27–39. doi: 10.1007/s11693-014-9135-9 PMID: 24592289